sabato, 17 ottobre 2026

Notizie AIOM – anno XVI n. 674

FDA approves new uses for two drugs administered together for the treatment of BRAF-positive anaplastic thyroid cancer

May 4, 2018 - The U.S. Food and Drug Administration approved dabrafenib and trametinib, administered together, for the treatment of anaplastic thyroid cancer (ATC) that cannot be removed by surgery or has spread to other parts of the body (metastatic), and has a type of ...
Leggi tutto

New Fellows Selected for ASCO’s 2018-2019 Health Policy Fellowship Program

May 2, 2018 - The American Society of Clinical Oncology (ASCO) announced today that Trevor Royce, MS, MD, MPH, and Sheetal Kircher, MD, have been selected for the ASCO Health Policy Fellowship Program. Now entering its third year, the fellowship program offers oncologists ...
Leggi tutto

NICE Recommends Midostaurin for FLT3+ AML

May 4, 2018 - The National Institute for Health and Care Excellence (NICE) has authorized the use of midostaurin in combination with standard chemotherapy for the treatment of patients with newly diagnosed FLT3-positive acute myeloid leukemia (AML), according to Novartis, ...
Leggi tutto

FDA Approves Tisagenlecleucel for Large B-Cell lymphoma

May 1, 2018 - The FDA has approved tisagenlecleucel for use in adult patients with relapsed/refractory large B-cell lymphoma-including diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma and DLBCL arising from follicular lymphoma-after 2 or more lines of systemic ...
Leggi tutto

FDA, FTC take action against companies misleading kids with e-liquids that resemble children’s juice boxes, candies and cookies

May 1, 2018 - As part of ongoing efforts to protect youth from the dangers of nicotine and tobacco products, today the U.S. Food and Drug Administration and the Federal Trade Commission (FTC) issued 13 warning letters to manufacturers, distributors, and retailers for selling ...
Leggi tutto

FDA Grants Orphan Drug Designation to BN-Brachyury for the Treatment of Chordoma

May 3, 2018 - On May 2, the U.S. Food and Drug Administration (FDA) granted orphan drug designation to the cancer vaccine BN-Brachyury for the treatment of chordoma. Chordoma is a rare type of cancer that develops along the spine, with presentation occurring at one of three ...
Leggi tutto

Efficacy, Safety, and Regulatory Approval of Food and Drug Administration-Designated Breakthrough and Nonbreakthrough Cancer Medicines

The breakthrough therapy program was established in 2012 to expedite the development and review of new medicines. We evaluated the times to approval, efficacy, and safety of breakthrough-designated versus non–breakthrough-designated cancer drugs approved by the US ...
Leggi tutto

Prognostic value of ki67 in BCG-treated non-muscle invasive bladder cancer: a meta-analysis and systematic review

The aim of this study was to explore the prognostic value of ki67 as a marker in patients with non-muscle invasive bladder cancer (NMIBC) treated with BCG. Studies were systematically retrieved from the relevant databases (Web of Science, PubMed, Cochrane Library and Embase), ...
Leggi tutto

FDA Grants Priority Review to Cemiplimab in CSCC

April 30, 2018 - The FDA has granted a priority review to a biologics license application (BLA) for the PD-1 inhibitor cemiplimab for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or patients with locally advanced CSCC who are not eligible ...
Leggi tutto

Chemotherapy-induced nausea and vomiting (CINV) in patients with advanced lung cancer during the first-line treatment: assessment by physicians, nurses, and patients from an Italian multicenter survey

Chemotherapy-induced nausea and vomiting (CINV) still represents a common side-effect of chemotherapy, and often, its perception differs between patients and healthcare professionals. The aim of this study was to evaluate the agreement on the perception of CINV and other ...
Leggi tutto